Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...
Beta Bionics Inc., a trailblazer in insulin delivery technology, made waves in the stock market Thursday after pricing an ...
Thursday marked the Nasdaq Global Market debut of Beta Bionics, Inc. as its initial public offering (IPO) opened for trading ...
People with diabetes have a higher risk of developing Alzheimer's disease (AD) raising a possible link between the cells that ...
Pancreas cells may produce a protein that can protect the brain from Alzheimer's disease. In individuals with Alzheimer's ...
Shares in the Irvine-based medical device company rose 29% to $23.64 and a $975 million market within the first three hours ...
While insulin resistance doesn’t always cause obvious symptoms, there are several signs to look out for. Increased fat around ...
Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...
Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering.
Someone is considered to be diabetic if the blood glucose/sugar levels are persistently above normal. People with diabetes usually have problems converting food nutrients into energy for their body ...
Irvine-based medical device company Beta Bionics Inc. on Jan. 6 filed an S-1 with the Securities and Exchange Commission to ...